immunoassay raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
Composition reflects both the original whey and the hydrolysis process. Products contain protein-derived peptides, variable ash, moisture, and residual lactose or fat depending on filtration. Some free amino acids increase during hydrolysis, and bitterness often rises with higher degrees of hydrolysis due to exposed hydrophobic residues. Mineral profiles vary with the whey source and any neutralization step. Allergenicity may be reduced in extensively hydrolyzed products, but the extent depends on residual intact protein and peptide size, and this remains a subject of ongoing study.
Whey protein hydrolysate is a dairy-derived ingredient made by treating whey protein with enzymes or acid to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese manufacture, which contains beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin, and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and taste. The extent of breakdown is described by degree of hydrolysis, a percentage of cleaved peptide bonds. This value influences functional and sensory properties but does not by itself define a specific molecular profile.
Advanced peptide profiling uses liquid chromatography coupled with mass spectrometry to identify fragments and assess batch consistency. Amino acid analysis after acid hydrolysis quantifies the building blocks and can reveal deviations from expected composition. Residual enzyme activity may be monitored in products where active enzymes are undesirable. Allergen tests often use immunoassays for beta-lactoglobulin, but hydrolysis can reduce or alter epitope recognition, so negative results do not prove absence of allergenic potential. Physical tests include particle size, bulk density, and reconstitution behavior.
Regulatory and labeling frameworks vary by country. In the United States, whey protein hydrolysate may be regulated as a food ingredient or a dietary supplement ingredient depending on intended use. In the European Union, it falls under general food law, with additional rules for infant formula and foods for special medical purposes. A claim of hypoallergenicity is not established by hydrolysis alone and generally requires clinical evidence. Open questions remain about how degree of hydrolysis relates to bitterness, nitrogen absorption, and residual allergenicity across different products and processing methods.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to cream powder | Color varies with source and drying. |
| Solubility | High in water; pH-dependent | Shorter peptides often dissolve more readily than intact protein. |
| Typical storage temperature | 15–25 °C, dry conditions | Cool, dry storage limits moisture uptake and browning. |
| Common analytical method | Kjeldahl or Dumas for total nitrogen | Estimates protein content; not peptide size. |
| Common synonyms | Hydrolyzed whey protein; whey peptide | Hydrolysate spelling is standard in scientific use. |
Composition reflects the whey source and the extent of hydrolysis. Beta-lactoglobulin and alpha-lactalbumin fragments are common, and sweet whey may contribute glycomacropeptide. The amino acid profile remains broadly similar to intact whey protein, but peptide size affects how quickly nitrogen appears in blood after ingestion. Bitter notes often arise from short peptides with hydrophobic residues. Hydrolysates are used in sports nutrition, infant formula, and clinical nutrition, though effects on muscle, immunity, or allergy risk are separate research questions rather than guaranteed properties.
Whey protein hydrolysate is derived from whey, the liquid byproduct of cheese-making or casein coagulation. It consists of peptides and free amino acids produced when peptide bonds are cleaved by enzymes or acid. Hydrolysis lowers the average molecular weight and can change solubility, viscosity, and bitterness. The degree of hydrolysis indicates the proportion of peptide bonds broken and distinguishes partial from extensive hydrolysates. Commercial ingredients vary widely in peptide size, mineral content, and lactose level.
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Whey protein hydrolysate is a dairy ingredient produced when whey proteins are treated with proteolytic enzymes or, less commonly, acid or heat under controlled conditions. The treatment cleaves peptide bonds and yields shorter peptide chains than those found in intact whey protein. The starting material is usually sweet whey or acid whey from cheese manufacture, concentrated by membrane filtration before hydrolysis. The resulting ingredient retains many amino acids from the original protein but differs in molecular size, solubility, and taste profile.
Quality control includes verifying identity, protein content, degree of hydrolysis, and absence of contaminants. Because hydrolysates are often used in foods and supplements, regulations may treat them as food ingredients rather than drugs. Allergen labeling rules can vary, and highly hydrolyzed products are sometimes considered less allergenic, but this depends on peptide size and clinical testing. Sourcing documents should link each lot to raw whey, enzymes, and processing conditions. Independent verification is useful because analytical results can shift with method and laboratory.
Laboratories characterize whey protein hydrolysate using several complementary methods. Nitrogen determination estimates total protein, while size-exclusion chromatography and mass spectrometry reveal peptide size distributions. Degree of hydrolysis can be calculated from free amino groups, pH change, or osmolarity, but each approach has assumptions. Moisture, ash, and mineral content are also measured because they affect shelf life and reconstitution. No single test fully describes a hydrolysate, so specifications usually combine several results.
=== Pregnant and lactating women === In North America, the IOM has set the RDA for pregnancy at 1.0 mg/day and for lactation at 1.3 mg/day. The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA. PRI for pregnancy is 1.6 mg/day, for lactation 1.6 mg/day – higher than the U.S. RDAs.
=== Software === EmberZNet PRO is a Zigbee protocol software package that runs the mesh networking applications. It provides networking for applications such as Advanced Metering Infrastructure (AMI), home automation Networks (HANs), and building automation systems. It is compliant with all the Ember chips.
Efforts to understand PQQ biosynthesis have contributed to broad interest in radical SAM enzymes and their ability to modify proteins, and an analogous radical SAM enzyme-dependent pathway has since been found that produces the putative electron carrier mycofactocin, using a valine and a tyrosine from the precursor peptide, MftA.
The LE cell was discovered in bone marrow in 1948 by Hargraves et al. In 1957 Holborow et al. first demonstrated ANA using indirect immunofluorescence. This was the first indication that processes affecting the cell nucleus were responsible for SLE. In 1959 it was discovered that serum from individuals with SLE contained antibodies that precipitated with saline extracts of nuclei, known as extractable nuclear antigens (ENAs). This led to the characterisation of ENA antigens and their respective antibodies. Thus, anti-Sm and anti-RNP antibodies were discovered in 1966 and 1971, respectively. In the 1970s, the anti-Ro/anti-SS-A and anti-La/anti-SS-B antibodies were discovered. The Scl-70 antibody was known to be a specific antibody to scleroderma in 1979, however the antigen (topoisomerase-I) was not characterised until 1986. The Jo-1 antigen and antibody were characterised in 1980.
Sources: en.wikipedia.org
The medial position (base) in this molecule (the isomer [1(2,3)4]pentamantane) is calculated to yield a more favorable carbocation than the apical position (top) and simple bromination of pentamantane 1 with bromine exclusively gives the medial bromo derivative 2 which on hydrolysis in water and DMF forms the alcohol 3.
Therefore almost all patients will in addition require immunosuppressants, such as prednisone, mycophenolate or azathioprine, as acetylcholinesterase inhibitors alone are insufficient. The surgical removal of the thymus may improve symptoms in certain cases. Plasmapheresis and high-dose intravenous immunoglobulin may be used when oral medications are insufficient to treat severe symptoms, including during sudden flares of the condition. On rare occasions the respiratory muscles can become significantly weak, subsequent mechanical ventilation may then be required. Once intubated, acetylcholinesterase inhibitors may be temporarily withheld to reduce airway secretions. Myasthenia gravis affects 50 to 200 people per million. It is newly diagnosed in 3 to 30 people per million each year. Increased awareness has made diagnosis more common. Myasthenia gravis most commonly occurs in women under the age of 40 and in men over the age of 60. It is uncommon in children. With treatment, most have fulfilling lives and have a normal life expectancy. The word is from the Greek mys, "muscle" and asthenia "weakness", and the Latin gravis, "serious".
As well as preliminary rulings on the proper interpretation of EU law, an essential function of the Court of Justice is judicial review of the acts of the EU itself. Under Treaty on the Functioning of the European Union (TFEU) article 263(1) the Court can review the legality of any EU legislative of other "act" against the Treaties or general principles, such as those in the Charter of Fundamental Rights of the European Union. This includes legislation, and most other acts that have legal consequences for people. For example, in Société anonyme Cimenteries CBR Cementsbedrijven NV v Commission the commission made a decision to withdraw an assurance to a Dutch cement company that it would be immune from competition law fines, for vertical agreements. The cement company challenged the decision, and the Commission argued this was not really an "act", and so could not be challenged. The Court of Justice held a challenge could be made, and it was an act, because it "deprived [the cement company] of the advantages of a legal situation... and exposed them to a grave financial risk". Similarly in Deutsche Post v Commission the Commission demanded information on state aid given by Germany to Deutsche Post within 20 days. When both challenged this, the Commission argued that the demand for information could not be an act as there was no sanction. The Court of Justice disagreed, and held judicial review could proceed because the request produced "binding legal effects" since the information supplied or not could be relied upon as evidence in a final decision.
==== National Strategy for Connected Schools ==== In September 2023, the government launched the National Strategy for Connected Schools (ENEC). The program is structured around four main connectivity pillars: deployment of high-speed internet access infrastructure; provision of adequate internet connectivity; installation of Wi-Fi networks in schools; and supply of electrical power. ENEC will receive investments of 8.8 billion reais, of which 6.5 billion reais come from the “Digital Inclusion and Connectivity” axis of the New PAC. Funding comes from four sources: the 5G auction, the Universal Service Fund for Telecommunications (Fust), the Connected Education Innovation Program (PIEC) and Law No. 14,172 of 2021.
Cyclofenil, sold under the brand name Sexovid among others, is a selective estrogen receptor modulator (SERM) medication which is used as a gonadotropin stimulant or ovulation inducer and in menopausal hormone therapy in women. It is mostly no longer available. The medication is taken by mouth. Side effects of cyclofenil include liver toxicity among others. It is a selective estrogen receptor modulator (SERM) and hence is a mixed agonist–antagonist of the estrogen receptor (ER), the biological target of estrogens like estradiol. It has antiestrogenic effects on the hypothalamic–pituitary–gonadal axis and hence can increase sex hormone production and stimulate ovulation. Cyclofenil was introduced for medical use in 1970. It has been mostly discontinued, but remains available in a few countries, including Brazil, Italy, and Japan. It has been used as a doping agent by male athletes.
Sources: en.wikipedia.org
It is whey protein that has been broken into smaller peptides and amino acids through enzymatic or acid hydrolysis. The resulting ingredient is used in food and nutritional products for its altered functional and sensory properties. It is not a single uniform substance because production conditions vary.
Hydrolysis targets peptide bonds, not lactose, so the lactose content depends mainly on the starting whey protein concentrate or isolate. Filtration steps before or after hydrolysis can reduce lactose. A hydrolysate labeled as isolate typically contains less lactose than one derived from concentrate.
No. Whey isolate refers to a high-protein, low-fat, low-lactose whey fraction, while hydrolysate refers to protein that has been cleaved into smaller peptides. A product can be both whey isolate and hydrolyzed. The terms describe different processing dimensions.
It is often estimated by TNBS, OPA, or pH-stat methods that quantify free amino groups or released protons. Values depend on assay conditions, protein standard, and calculation method. No single universal protocol exists for all products.